

AMERICAN SOCIETY FOR EXPERIMENTAL NEUROTHERAPEUTICS

ASENT

16th Annual Meeting


February 20 – 22, 2014

**Bethesda North Marriott Hotel & Conference Center
Bethesda, Maryland**

Vision Statement

**To advance the science of neurotherapeutics and
to improve and accelerate the development
of new treatments.**

PROGRAM BOOK



342 North Main Street, Suite 301
West Hartford, CT 06117-2507

Phone: 860-586-7570 • Fax: 860-586-7550 • Email: info@asent.org

ASENT Corporate Partners

List as of February 13, 2014

Platinum \$25,000 +

**Eisai, Inc.
Janssen Scientific Affairs, Inc.**

Gold \$10,000 - \$24,999

**Allergan, Inc.
Biogen Idec, Inc.
Bracket Global
Lundbeck, Inc.**

Silver \$5,000 - \$9,999

**INC Research, LLC
PPD, Inc.
SK Biopharmaceuticals/SK Life Science
UCB, Inc.
Upsher-Smith Laboratories, Inc.**

Bronze \$2,500 - \$4,999

**Acorda Therapeutics, Inc.
KM Pharmaceutical Consulting, LLC
PAREXEL International
Worldwide Clinical Trials Holdings, Inc.**


Supporter \$1,000 - \$2,499

**Chase Pharmaceuticals Corporation
Cytokinetics, Inc.
NeuroPace, Inc.
Zalicus, Inc.**

Table of Contents


| | |
|---|------------|
| Meeting Room Layout | 2 - 3 |
| Program Schedule | 4 |
| Information Exchange and Poster Presentations | 6 |
| Annual Business Meeting | 10 |
| Meeting Evaluation/How Do I Obtain CME Credits? | 14 |
| Continuing Medical Education Information..... | 15 |
| 16th Annual Meeting Program Committee | 19 |
| ASENT Board of Directors | 20 |
| Schedule-At-A-Glance..... | Back Cover |

American Society for Experimental NeuroTherapeutics



Main Level

American Society for Experimental NeuroTherapeutics



Lower Level

American Society for Experimental NeuroTherapeutics

Program Schedule

WEDNESDAY, FEBRUARY 19, 2014

6:00 p.m. – 8:00 p.m.

*Grand Ballroom C,
Main Level*

Welcome Reception

THURSDAY, FEBRUARY 20, 2014

8:00 a.m. – 12:00 p.m.

*Grand Ballroom A/B,
Main Level*

**Commonalities in the Development of
Clinical Trial Measures in Neurology**

Program

Co-Chairs: Jesse Cedarbaum, MD, Consultant; Robin Elliott, MA, Parkinson's Disease Foundation; Karl Kieburtz, MD, University of Rochester; Marc Walton, MD, PhD, FDA

8:00 a.m. – 8:05 a.m.

Presidential Welcome

Michael Rogawski, MD, PhD, University of California, Davis

8:05 a.m. – 8:25 a.m.

Introduction

Marc Walton, MD, PhD, FDA

8:25 a.m. – 8:45 a.m.

CAMD and C-Path Introduction

Diane Stephenson, PhD, Critical Path Institute

8:45 a.m. – 9:00 a.m.

C-Path MS Outcomes Assessment Consortium

Richard Rudick, MD, Cleveland Clinic

9:00 a.m. – 9:15 a.m.

Alzheimer's Association Alzheimer's Disease Initiatives

Maria Carrillo, PhD, Alzheimer's Association

9:15 a.m. – 9:30 a.m.

Parkinson's Disease: Updating the UPDRS

Glenn Stebbins, PhD, Rush University Medical Center

9:30 a.m. – 9:45 a.m.

Motor Neuron Diseases

Douglas Kerr, MD, PhD, Biogen Idec

9:45 a.m. – 10:00 a.m.

Panel Discussion

10:00 a.m. – 10:20 a.m.

Break

10:20 a.m. – 10:40 a.m.

NIMH Research Domain Criteria Initiative (RDoC): A Framework for Psychopathology Research

Jill Heemscker, PhD, NIMH/NIH

10:40 a.m. – 11:00 a.m.

NINDS-CDE

Wendy Galpern, MD, NINDS/NIH

11:00 a.m. – 11:20 a.m.

Outcome Measures for Neurological Trials

Petra Kaufmann, MD, MSc, NINDS/NIH

11:20 a.m. – 11:40 a.m.

Including the Patient Voice in the Development of Rating Scales

David Cella, PhD, Northwestern University

11:40 a.m. – 12:00 p.m.

Wrap-Up Discussion

Laurie Burke, RPh, MPH, LORA Group, LLC
Maria Isaac, MD, PhD, European Medicines Agency
Billy Dunn, MD, FDA

American Society for Experimental NeuroTherapeutics

Program Schedule (Continued)

THURSDAY, FEBRUARY 20, 2014

12:00 p.m. – 1:15 p.m.

*White Oak,
Lower Level*

Clinical Trial Measures Working Groups Luncheon

- Incorporating the Patient Voice in the Presence of Cognitive Limitation
- Assessing ADLs Across Indications
- Developing New Instruments: Starting from Scratch vs. Composites of Existing Items
- Assessment of Motor Function Across Neurological Diseases
- Assessing Cognition Across Neurological Diseases
- Assessment of Sensory Function Across Diseases
- Assessing Mood and Anxiety in Neurological Disorders
- Issues in AD
- Issues in PD
- Issues in MS
- Issues in ALS

1:15 p.m. – 1:45 p.m.

*White Oak,
Lower Level*

Reports and Wrap-Up

2:00 p.m. – 5:00 p.m.

*Grand Ballroom A/B,
Main Level*

Science Non-Fiction in Neurotherapeutics

Program

Chair: Martha Morrell, MD, NeuroPace, Inc.

2:00 p.m. – 2:05 p.m.

Welcome and Introduction

Martha Morrell, MD, NeuroPace, Inc.

2:05 p.m. – 2:35 p.m.

Applications of Nanotechnology for Treatment of Diseases of the Nervous System

Gabriel Silva, PhD, UCSD Jacobs Retina Center

2:35 p.m. – 3:05 p.m.

Optogenetics: Tools for Analyzing and Repairing the Nervous System

Anthony Zoros, PhD, MIT Media Lab

3:05 p.m. – 3:20 p.m.

Break

3:20 p.m. – 3:50 p.m.

Reliable Neural Interfaces for Neurotherapeutics

Jack Judy, MD, PhD, Nanoscience Institute for Medical and Engineering Technology, University of Florida

**American Society for
Experimental NeuroTherapeutics**

**Information Exchange and
Poster Presentations**

Thursday, February 20, 2014

5:00 p.m. – 6:30 p.m.

Grand Ballroom C, Main Level

Authors Present

Since 1999, ASENT has sponsored a poster session of new and previously unpublished data from physicians, researchers and this industry in the field of neurotherapeutics. All posters are peer reviewed, and accepted posters will also be published in ASENT's journal, *Neurotherapeutics*[®].

In addition, previously published data, preliminary data and/or previously reviewed posters are also welcome. These posters will not be published in the journal.

The poster session is an opportune time for academicians to showcase potential therapeutic opportunities to the industry and for the industry to provide review data on the progress of their approved or unapproved therapies. Join us in the poster session, and meet the presenters and discuss their projects.

(See the Abstract Descriptions handout available at the Information Exchange.)

American Society for Experimental NeuroTherapeutics

Program Schedule (Continued)

THURSDAY, FEBRUARY 20, 2014

| | |
|-----------------------|--|
| 3:50 p.m. – 4:20 p.m. | Brain Machine Interfaces for Language Protheses Brian Pasley, PhD, Helen Wills Neuroscience Institute, University of California, Berkeley |
| 4:20 p.m. – 4:30 p.m. | CDRH Office of Science and Engineering Laboratories Victor Krauthamer, PhD, FDA, CDRH and OSEL |
| 4:30 p.m. – 5:00 p.m. | Panel Discussion |

3:30 p.m. – 5:00 p.m.
Animal Research and Brain Diseases
*Linden Oak,
Lower Level*

Hosted by the American Brain Coalition and the Society for Neuroscience, with support from the Esther A. & Joseph Klingenstein Fund, Inc.

Humane and well-regulated animal research is an essential component in the development of treatments for brain diseases. Hear perspectives from a scientist, a clinician, and a patient, and engage in a thoughtful conversation on the importance of animal research. The panel will be moderated by Mark Rasenick, distinguished University of Chicago professor and American Brain Coalition Advocacy Chair, who studies the neuroscience of depression and antidepressants.

5:00 p.m. – 6:30 p.m.
**Information Exchange and Poster
Presentation Reception**
*Grand Ballroom C,
Main Level*

6:30 p.m. – 8:30 p.m.
Dinner Session: Conflict of Interest
*Grand Ballroom A/B,
Main Level*

Program

Co-Chairs: Mitchell Brin, MD, Allergan, Inc.; Kathleen Clarence-Smith, MD, PhD, KM Pharmaceutical Consulting LLC

| | |
|-----------------------|---|
| 7:00 p.m. – 7:10 p.m. | Alan Faden, MD, Neurotherapeutics® Editor-in-Chief, Ten Volumes of Excellence Presentation made by Howard Federoff, MD to Alan Faden, MD |
| 7:15 p.m. – 8:30 p.m. | Conflict of Interest Speakers: Josephine Torrente, JD, Hyman, Phelps & McNamara; Sheila Walcoff, JD, Goldbug Strategies LLC |

American Society for Experimental NeuroTherapeutics

Program Schedule (Continued)

FRIDAY, FEBRUARY 21, 2014

7:30 a.m. – 9:00 a.m.
*Grand Ballroom A/B,
Main Level*

Cognition Workshop

Program

Co-Chairs: Amy Chappell, MD; Jill Rasmussen, MD, Psi-Napse

7:30 a.m. – 7:40 a.m.

Introduction

7:40 a.m. – 8:10 a.m.

Designing a Battery for Clinical Trials: The MATRICS Project for Schizophrenia

Richard Keefe, PhD, Duke University Medical Center

8:10 a.m. – 8:40 a.m.

The Problem of Cognitive Dysfunction/Decline in Epilepsy

Kimford Meador, MD, Stanford University School of Medicine

8:40 a.m. – 9:00 a.m.

Panel Discussion

9:15 a.m. – 12:30 p.m.
*Grand Ballroom C,
Main Level*

Psychiatric Pharmacogenomics: From Single DNA Nucleotides to Improved Patient Care

Program

Chair: C. Anthony Altar, PhD, AssureRx Health, Inc.

9:15 a.m. – 9:25 a.m.

Introduction

9:25 a.m. – 10:00 a.m.

Gene Polymorphisms: How They Alter Enzymes, Transporters and CNS Response Proteins

Andrea Gaedigk, PhD, Children's Mercy Hospitals and Clinics

10:00 a.m. – 10:35 a.m.

Challenges in Bringing Psychiatric Pharmacogenomics to the Clinic

Roy Perlis, MD, MSc, Massachusetts General Hospital

10:35 a.m. – 11:10 a.m.

Using Combinatorial Pharmacogenomics to Predict and Improve Antidepressant Outcomes

C. Anthony Altar, PhD, AssureRx Health, Inc.

11:10 a.m. – 11:25 a.m.

Break

11:25 a.m. – 12:10 p.m.

Next-Generation Sequencing Pharmacogenomics for Psychiatry and CNS Therapeutics

Richard Weinshilboum, MD, Mayo Clinic

12:10 p.m. – 12:30 p.m.

Panel Discussion

American Society for Experimental NeuroTherapeutics

Program Schedule (Continued)

FRIDAY, FEBRUARY 21, 2014

12:45 p.m. – 2:00 p.m.
White Oak
Lower Level

Special Interest Topics and Luncheon

- Health Information Technology (HIT) as a Tool to Enable Comparative Effectiveness Research
- How Can Phase I Inform Efficacy?
- What are Appropriate Expectations for Animal Models?
- How to Most Efficiently Find the Right Dose
- How to use Social Media to Engage Patients in Clinical Research
- Innovation in Clinical Patient Data Collection: Use of Smart Phones and Other Remote Monitoring Techniques
- Challenges to Young Researchers Entering the Field of Neurotherapeutics
- Challenges to International Drug Development
- Drug Development and Health Care Reform
- How Much Safety Must We Have to Support Marketing Authorization and to Get to Phase III Trials?
- Challenges for Start-Up Companies to Achieve Proof of Concept

2:15 p.m. – 6:00 p.m.
Grand Ballroom A/B,
Main Level

Pipeline Session

Chair: Philip Perera, MD, Dart Neuroscience LLC

Investigators in academia, government, industry and advocacy present an update on research and development progress on a specific project in the broad area of neurotherapeutics. Such projects may address neurological disorders, psychiatric disorders, pain, neuro-oncology, neurological infections or any other disorder affecting the central or peripheral nervous systems.

Annual Business Meeting

**Saturday, February 22, 2014
Bethesda North Marriott Hotel &
Conference Center**

Grand Ballroom A/B, Main Level

8:30 a.m. - 9:00 a.m.

Preliminary Agenda

- I. Call to Order
- II. Financial Report
- III. *Neurotherapeutics*[®] Journal Report
- IV. Membership Report
- V. 17th Annual Meeting, February 2015
- VI. Recognition of Outgoing Board Members
- VII. Introduction of Incoming Board Members
- VIII. Adjournment

American Society for Experimental NeuroTherapeutics

Program Schedule (Continued)

SATURDAY, FEBRUARY 22, 2014

8:30 a.m. – 9:00 a.m.

*Grand Ballroom A/B,
Main Level*

ASENT Annual Business Meeting

CONCURRENT SESSIONS:

9:00 a.m. – 2:00 p.m.

9:10 a.m. – 11:45 a.m.

*Grand Ballroom A/B,
Main Level*

Gene Therapy

Program

Chair: Howard Federoff, MD, PhD, Georgetown University

9:10 a.m. – 9:20 a.m.

**Overview of CNS Gene Transfer as an Evolving
Neurotherapeutic Modality**

Howard Federoff, MD, PhD, Georgetown University

9:20 a.m. – 9:35 a.m.

**FDA Regulatory Approach for Gene Therapy
Clinical Trials**

Denise Gavin, PhD, FDA

9:35 a.m. – 9:55 a.m.

AADC Gene Transfer for Movement Disorders

Krystof Bankiewicz, MD, PhD, University of California,
San Francisco

9:55 a.m. – 10:15 a.m.

Prosavin Gene Transfer to Parkinson's Disease

Stephane Palfi, MD, Henri Mondor Hospital

10:15 a.m. – 10:30 a.m.

**Using Functional Imaging to Measure Gene Transfer
Function**

David Eidelberg, MD, Feinstein Institute for Medical
Research

10:35 a.m. – 10:45 a.m.

Break

10:45 a.m. – 11:45 a.m.

Panel Discussion

11:45 a.m.

Annual Meeting Adjourns

American Society for Experimental NeuroTherapeutics

Program Schedule (Continued)

SATURDAY, FEBRUARY 22, 2014

9:00 a.m. – 2:00 p.m.

**Grand Ballroom C,
Main Level**

**Nuts, Bolts and Best Practices in the
Conduct of Clinical Trials**

Program

Co-Chairs: Jesse Cedarbaum, MD, Consultant; Adam Butler, Bracket Global; Bernard Ravina, MD, Biogen Idec; Jeremy Shefner, MD, PhD, Upstate University Hospital

| | |
|-------------------------|--|
| 9:00 a.m. – 9:05 a.m. | Welcome and Introduction Session Co-Chairs |
| 9:05 a.m. – 9:25 a.m. | The Regulatory Framework for Drug Development Wilson Bryan, MD, FDA |
| 9:25 a.m. – 9:45 a.m. | Managing Clinical Trials in Your Practice: Site Management/Logistics Craig Curtis, MD, CPI, Compass Research |
| 9:45 a.m. – 10:05 a.m. | Managing Clinical Trials in Your Practice: Negotiation Prior to Start-Up Cornelia Kamp, MBA, University of Rochester |
| 10:05 a.m. – 10:25 a.m. | Managing Clinical Trials in Your Practice: Interfacing with the Operations Team Elizabeth Jones, RN, PAREXEL International |
| 10:25 a.m. – 10:45 a.m. | Managing Clinical Trials in Your Practice: Data Donna Hellsten, PPD |
| 10:45 a.m. – 11:05 a.m. | Managing Clinical Trials in Your Practice: Safety Reporting and SAE Management Mark Hosterman, INC Research |
| 11:05 a.m. – 11:25 a.m. | Managing Clinical Trials in Your Practice: What is an Audit and What to do if a Company or the FDA Audits You Elizabeth Troll, Quintiles |
| 11:25 a.m. – 11:55 a.m. | Break |
| 11:55 a.m. – 12:15 p.m. | The “Intangibles:” Patient Recruitment and Retention Karen Bell, MD, Columbia University |
| 12:15 p.m. – 12:35 p.m. | The “Intangibles:” What is “Informed” Consent? E. Ray Dorsey, MD, MBA, University of Rochester |

**American Society for
Experimental NeuroTherapeutics**

Program Schedule (Continued)

SATURDAY, FEBRUARY 22, 2014

- 12:35 p.m. – 12:55 p.m. **The “Intangibles:” Quality, Quality, Quality**
David Miller, MD, Bracket Global
- 12:55 p.m. – 1:15 p.m. **The “Intangibles:” The Importance of Training**
Amy Veroff, Cogstate
- 1:15 p.m. – 1:30 p.m. **The “Intangibles:” What Sponsors/
Groups Look for from Industry**
O’Neill D’Cruz, MD, MBA, UCB, Inc.
- 1:30 p.m. – 1:45 p.m. **The “Intangibles:” What Sponsors/
Groups Look for from Academic Consortia**
James Caress, MD, Wake Forest University School of
Medicine
- 1:45 p.m. – 2:00 p.m. **Panel Discussion: Interpreting Clinical Trial Data
and Discussing New Outcomes with Patients**
Jesse Cedarbaum, MD, Moderator
- 2:00 p.m. **Adjourn**

Meeting Evaluation/ How Do I Obtain CME Credits?

To obtain a CME certificate for the ASENT 16th Annual Meeting, please access the online evaluation on our website, www.asent.org. A link to the evaluation is on the homepage. Evaluations must be completed by **Saturday, March 22, 2014**, in order to receive credit.

ASENT's 16th Annual Meeting has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Vermont and the American Society for Experimental NeuroTherapeutics. The University of Vermont is accredited by the ACCME to provide continuing medical education for physicians.

The University of Vermont designates this live activity for a maximum of 17 AMA *PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Your number of credits will be determined based on the questions you answer in the online evaluation.

Continuing Medical Education Statement and Session Objectives

Session Objectives: At the completion of the meeting, participants will be able to:

- Create trial designs that comply with standardized clinical trials measures that are acceptable and approved by pharmaceutical companies, government agencies, FDA, investigators and patient populations and that would be coordinated to avoid confusion and subsequently allow learners to prepare new protocols without errors, redundancy or omissions, ultimately streamlining the review process; and
- Obtain updated information regarding gene polymorphisms, how they alter drug metabolism, protein degradation in various patient populations exposed to medications. Participant should be able to use pharmacogenomics responses to predict outcomes clinically utilizing psychiatric drugs as a basis for model design.

Meeting Disclaimer: Regarding written materials and information received, written or otherwise, during this activity: The scientific views, statements and recommendations expressed during this CME activity represent those of the authors, and speakers and do not necessarily represent the views of the University of Vermont.

Interest Disclosures: As an organization accredited by the ACCME to sponsor continuing medical education activities, The University of Vermont is required to disclose any real or apparent conflicts of interest (COI) that any speakers may have related to the content of their presentations.

The University of Vermont requires that each speaker participating in a program designated for AMA Physician's Recognition Award Category 1 credit disclose any financial interest/arrangement or affiliation with a corporate organization that may impact on his/her presentation (i.e. grants, research support, honoraria, member of speakers' bureau, consultant, major stock shareholder, etc.)

No Interests to Disclose:

Wilson Bryan, MD
Laurie Burke, RPh, MPH
James Caress, MD
Maria Carrillo, PhD
Jesse Cedarbaum, MD**
David Cella, PhD
Amy Chappell, MD**
E. Ray Dorsey, MD, MBA
David Eidelberg, MD
Robin Elliott, MA**
Andrea Gaedigk, PhD
Wendy Galpern, MD, PhD
Denise Gavin, PhD
Robert Hamill, MD**
Jill Heemskerk, PhD
Jack Judy, MD

Petra Kaufmann, MD, MSc
Kevin Keim, PhD, MSc
Douglas Kerr, MD, PhD
Victor Krauthamer, PhD
Bennett Lavenstein, MD**
Martha Morrell, MD**
Brian Pasley, PhD
Gabriel Silva, PhD
Glenn Stebbins, PhD
Diane Stephenson, PhD
Josephine Torrente, JD
Amy Veroff
Sheila Walcoff, JD
Marc Walton, MD, PhD**
Richard Weinshilboum, MD
Antony Zorzos, PhD

**Continuing Medical Education
Statement and Session Objectives**

(Continued)

Interests to Disclose/COI/Bias Resolved*:

C. Anthony Alter, PhD**

AssureRx Health, Inc., employee

Krystoff Bankiewicz, MD, PhD

Voyager Therapeutics, financial interest; uniQuire, financial interest

Karen Bell, MD

Baxter, stock; Pfizer, research support

Mitchell Brin, MD**

Allergan, employee

Adam Butler**

Bracket Global LLC, employee; ExpressScripts Inc, shareholder

Kathleen Clarence-Smith, MD, PhD**

KM Pharmaceutical Consulting, employee; Chase Pharmaceuticals,
chairman; Kurma Bofnd, consultant; Key Neuroscience, consultant

Shaun Comfort, MD**

Adaptix Clinical Solutions, LLC, employee; Incline Therapeutics,
consultant; Cyberonics, consultant; Invictus Medical, consultant;
Anthera Pb, consultant

O'Neill D'Cruz, MD, MBA

UCB Pharma, employee

Donna Hellsten, PPD

employee

Mark Hosterman, PharmD

INC Research, employee

Elizabeth Jones, RN

PAREXEL International, employee

Cornelia Kamp, MBA

Clintrex, LLC, consultant

**Continuing Medical Education
Statement and Session Objectives**

(Continued)

Richard Keefe, PhD

Investigator-initiated research funding support from Dept. of Veteran's Affairs, Feinstein Institute for Medical Research, GlaxoSmithKline, NIH/NIMH, Novartis, Psychogenics, Research Foundation for Mental Hygiene, and Singapore National Medical Research Council; received honoraria, served as a consultant, or advisory board member for Abbvie, Akebia, Amgen, Astellas, Asubio, AviNeuro/ChemPar, BiolineRx, Biomarin, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, EnVivo, Helicon, Lundbeck, Merck, Mitsubishi, Otsuka, Pfizer, Roche, Shire, Sunovion, Takeda, Targacept

Kimford Meador, MD

NIH/NINDS, research grants; UCB Pharma, research grants; Epilepsy Study Consortium, consultant

David Miller, MD

Bracket Global, employee; Express Scripts, stockholder

Martha Morrell, MD**

NeuroPace, Inc., employee

Stephane Palfi, MD

Oxford Biomedica, honorarium

Philip Perera, MD**

Dart NeuroScience, employee

Roy Perlis, MD, MSc

Genomind, consultant; PsyBrain, consultant; Proteus, consultant; PamLab, consultant; Pfizer, consultant; RIDVentures, consultant

Roger Porter, MD**

Lilly, consultant; NeruoPace, consultant; Upsher-Smith, consultant; Medivation, consultant; Civitas, consultant; Astellos, consultant; SK Pharma, consultant

Jill Rasmussen, MD**

Psi-Napse, director

Bernard Ravina, MD, MS

Biogen Idec, employee and stock holder

Nancy Santilli, MSN**

Endo Health Solutions, employee

**American Society for
Experimental NeuroTherapeutics**

**Continuing Medical Education
Statement and Session Objectives**
(Continued)

Jeremy Shefner, MD, PhD

Cytokinetics, consultant; ISIS, consultant; Synaerion, consultant

William Theodore, MD**

Common stock ownership in IBM, CSCO, XOM, PG, SJM, HON

*Having a financial interest or other relationship with a corporate organization may not prevent a speaker from making a presentation; however, the existence of the relationship must be made known to the planning committee prior to the conference so that any possible conflict of interest may be resolved prior to the talk.

**ASENT Program Committee

**American Society for
Experimental NeuroTherapeutics**

**16th Annual Meeting
Program Committee**

Bennett Lavenstein, MD, Co-Chair
Children's Hospital Medical Center

Martha Morrell, MD, Co-Chair
NeuroPace, Inc.

C. Anthony, Altar, PhD
AssureRx Health, Inc.

Mitchell Brin, MD
Allergan, Inc.

Jesse Cedarbaum, MD
Consultant

Amy Chappell, MD

Kathleen Clarence-Smith, MD, PhD
KM Pharmaceutical Consulting, LLC

Shaun Comfort, MD, MBA
Adaptix Clinical Solutions, LLC

Robin Elliott, MA
Parkinson's Disease Foundation

Robert Hamill, MD
University of Vermont

Philip Perera, MD
Dart Neuroscience LLC

Roger Porter, MD

Jill Rasmussen, MD
Psi-Napse

William H. Theodore, MD
National Institutes of Health

**American Society for
Experimental NeuroTherapeutics**

**ASENT 2013 - 2014
Board of Directors**

PRESIDENT

Michael Rogawski, MD, PhD
University of California, Davis

PRESIDENT-ELECT

Howard Federoff, MD, PhD
Georgetown University

IMMEDIATE PAST PRESIDENT

Robert W. Hamill, MD
University of Vermont

SECRETARY

Jesse Cedarbaum, MD
Consultant

TREASURER

Robin Elliott, MA
Parkinson's Disease Foundation

DIRECTORS 2011-2014

Rohit Bakshi, MD, FAAN
Brigham and Women's Hospital

Russell Katz, MD

Jill Rasmussen, MD
Psi-Napse

Richard Rudick, MD
Cleveland Clinic

DIRECTORS 2012-2015

Steven DeKosky, MD
University of Virginia School of
Medicine

Robert Griggs, MD
University of Rochester

Philip Perera, MD, MBA
Dart NeuroScience LLC

DIRECTORS 2013-2016

Timothy Coetzee, Ph.D.
National Multiple Sclerosis Society

Joseph Hulihan, M.D.
Janssen Global Services

Lynn Kramer, M.D.
Eisai, Inc.

Bernard Ravina, M.D.
Biogen Idec, Inc.

EX-OFFICIO

DEVELOPMENT COMMITTEE CHAIR
Kathleen Clarence-Smith, MD, PhD
KM Pharmaceutical Consulting, LLC

NEUROTHERAPEUTICS® EDITOR-IN-CHIEF
Alan Faden, MD

University of Maryland School of
Medicine

PROGRAM COMMITTEE CO-CHAIRS
Bennett Lavenstein, MD

Children's Hospital Medical Center

Martha Morrell, MD
NeuroPace, Inc.

NIH BLUEPRINT COURSE LIAISON
Barbara Slusher, PhD, MBA

Johns Hopkins School of Medicine

FEDERAL LIAISON

Rajesh Ranganathan, PhD
NIH/NINDS

EXECUTIVE DIRECTOR

Charles H. Marsh, CAE, IOM



American Society for Experimental
NeuroTherapeutics, Inc.

FUTURE MEETINGS

ASENT 17th Annual Meeting

February 19 – 21, 2015

Georgetown University Hotel &
Conference Center
Washington, D.C.

Abstract submissions begin
June 2, 2014

ASENT/ISCTM Joint Educational Session

February 19, 2015
Fairmont Hotel
Washington, D.C.

Schedule-At-A-Glance

Wednesday, February 19, 2014

5:30 p.m. – 8:00 p.m. Registration
Foyer, Grand Ballroom C, Main Level

6:00 p.m. – 8:00 p.m. Welcome Reception
Grand Ballroom C, Main Level

Thursday, February 20, 2014

7:30 a.m. – 6:00 p.m. Registration
Foyer, Grand Ballroom C, Main Level

8:00 a.m. – 12:00 p.m. Commonalities in the Development of Clinical Trial Measures in Neurology
Grand Ballroom A/B, Main Level

12:00 p.m. – 1:15 p.m. Clinical Trial Measures Working Groups Luncheon
White Oak, Lower Level

1:15 p.m. – 1:45 p.m. Clinical Trial Measures Reports and Wrap-Up
White Oak, Lower Level

2:00 p.m. – 5:00 p.m. Science Non-Fiction in Neurotherapeutics
Grand Ballroom A/B, Main Level

3:30 p.m. – 5:00 p.m. Animal Research and Brain Diseases
Linden Oak, Lower Level

5:00 p.m. – 6:30 p.m. Information Exchange and Poster Presentation Reception
Grand Ballroom C, Main Level

6:30 p.m. – 8:30 p.m. Dinner Session – Conflict of Interest
Grand Ballroom A/B, Main Level

FRIDAY, FEBRUARY 21, 2014

7:30 a.m. – 6:00 p.m. Registration
Foyer, Grand Ballroom C, Main Level

7:30 a.m. – 9:00 a.m. Cognition Workshop
Grand Ballroom A/B, Main Level

9:15 a.m. – 12:30 p.m. Psychiatric Pharmacogenomics: From Single DNA Nucleotides to Improved Patient Care
Grand Ballroom A/B, Main Level

12:45 p.m. – 2:00 p.m. Special Interest Topics and Luncheon
White Oak, Lower Level

2:15 p.m. – 6:00 p.m. Pipeline Session
Grand Ballroom A/B, Main Level

SATURDAY, FEBRUARY 22, 2014

8:00 a.m. – 12:00 p.m. Registration
Foyer, Grand Ballroom C, Main Level

8:30 a.m. – 9:00 a.m. Annual Business Meeting
Grand Ballroom A/B, Main Level
All members are welcome!

9:00 a.m. – 2:00 p.m. Nuts, Bolts and Best Practices in the Conduct of Clinical Trials
Grand Ballroom C, Main Level

9:10 a.m. – 11:45 a.m. Gene Therapy
Grand Ballroom A/B, Main Level



ASENT
342 North Main Street, Suite 301
West Hartford, CT 06117-2507
Phone: 860-586-7570 | Fax: 860-586-7550
Email: info@asent.org | www.asent.org